MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    How does a diagnosis of Dementia with Parkinson’s influence future care provision?

    B. Mohamed, A. Rafeeq, J. Adenwalla, C. Thomas, S. Page, R. Lewis-Morton, T. Williams, S. Mahon (cardiff, United Kingdom)

    Objective: To describe the trajectory of Parkinson’s after the onset of dementia including setting of care, frailty levels and mortality rate. Background: Cardiff and Vale…
  • 2023 International Congress

    Is a Parkinson’s Sialorrhoea service effective?

    C. Williams, J. Adenwalla, B. Mohamed, C. Marquis, C. Thomas, R. Lewis-Morton (cardiff, United Kingdom)

    Objective: Evaluate the efficacy and tolerance of Botulinum Toxin A (BoNT A) in managing sialorrhoea in People with Parkinsons (PwP)Assess impact on quality of life…
  • 2023 International Congress

    Trial site factor in Parkinson’s disease (PD) diary non-compliance

    P. Reksoprodjo (Prague, Czech Republic)

    Objective: In this analysis, we wanted to explore if PD diary non-compliance is distributed randomly in the dataset or if it has a tendency to…
  • 2023 International Congress

    Olfactory neurons’ Substance P is highly expressed in Parkinson’s disease reflecting gastrointestinal dysfunction

    T. Schirinzi, D. Maftei, P. Grillo, R. Bovenzi, J. Bissacco, C. Simonetta, H. Zenuni, FM. Passali, S. Di Girolamo, A. Stefani, NB. Mercuri, R. Lattanzi, C. Severini (Rome, Italy)

    Objective: To elucidate the role of Substance P in PD through molecular characterization of patients’ olfactory neurons. Background: Substance P is a neuropeptide largely expressed…
  • 2023 International Congress

    Longitudinal CSF measurements of alpha-synuclein, amyloid beta and tau in Parkinson disease

    R. Miller, A. Li, M. Campbel, J. Perlmutter, P. Kotzbauer (St. Louis, USA)

    Objective: To evaluate whether cerebrospinal fluid (CSF) levels of alpha synuclein (Asyn), amyloid beta (Aβ) and tau change with disease progression and to evaluate whether…
  • 2023 International Congress

    Cardiovascular autonomic function in GBA-associated Parkinson’s disease: a cross-sectional study

    T. de Santis, A. Cocco, P. Polverino, V. Polvere, EM. Valente, A. Albanese (Rozzano, Italy)

    Objective: To objectively assess cardiovascular autonomic function in patients with Parkinson’s disease (PD) carrying pathogenic variants of beta-glucocerebrosidase gene (GBA-PD) and compare to non-mutated PD…
  • 2023 International Congress

    The Roche ‘End-to-End Matrix’ for Patient-Centric Drug Discovery and Development – Focus on Parkinson’s disease

    A. Paehler, A. Stepan, E. Mracsko, K. Taylor, B. Zinnhardt, H. Binch, L. Gobbi, T. Luebbers, A. Olivares, R. Rodriguez Sarmiento, U. Grether, S. Dudal, G. Pagano (Basel, Switzerland)

    Objective: To develop an ‘End-to-End Matrix’ for Patient-Centric Drug Discovery and Development to increase the probability of success of clinical trials in Parkinson’s disease. Background:…
  • 2023 International Congress

    An Algorithmic Approach to Assessing Cognitive Functioning in Individuals with REM Sleep Behavior Disorder

    G. Schneider, A. Avidan, D. Bliwise, S. Criswell, E. During, J. Elliott, L. Forsberg, J-F. Gagnon, M. Howell, D. Huddleston, A. Keil, J. Lee-Iannotti, M. Lim, J. Mcleland, M. Miglis, E. Mignot, R. Postuma, C. Schenck, D. Shprecher, E. ST. Louis, A. Videnovic, B. Boeve, Y-E. Ju, J. Fields (Rochester, USA)

    Objective: To apply an algorithmic approach to interpretation of cognitive data to assess cognitive impairment in RBD participants. Background: Cognitive changes in emerging neurodegenerative disease…
  • 2023 International Congress

    Distinct striatal connectivity patterns in patients with Parkinson’s disease with and without urinary symptoms

    N. Piramide, R. de Micco, F. Di Nardo, M. Siciliano, G. Caiazzo, G. Tedeschi, F. Esposito, A. Tessitore (Napoli, Italy)

    Objective: To investigate the potential effect of urinary symptoms on the regional striatal functional connectivity (FC) in a cohort of drug-naïve PD patients applying a…
  • 2023 International Congress

    Keeping patients out of care facilities— clozapine rescues Parkinson’s patients with troublesome psychosis unresponsive to quetiapine and pimavanserin.

    J. Iseringhausen, G. Riboldi, K. Astudillo, S. Frucht (New York, USA)

    Objective: We describe a single-center cohort of Parkinson patients in crisis with troublesome psychosis unresponsive to quetiapine and pimavanserin, who were rescued by treatment with…
  • « Previous Page
  • 1
  • …
  • 584
  • 585
  • 586
  • 587
  • 588
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley